|
NZ334344A
(en)
*
|
1996-09-12 |
2000-08-25 |
Cancer Res Campaign Tech |
benzo[e]indole and pyrrolo[3,2-e]indole compounds and their use as prodrugs
|
|
US6130237A
(en)
*
|
1996-09-12 |
2000-10-10 |
Cancer Research Campaign Technology Limited |
Condensed N-aclyindoles as antitumor agents
|
|
GB9712370D0
(en)
|
1997-06-14 |
1997-08-13 |
Aepact Ltd |
Therapeutic systems
|
|
EP0887348A1
(en)
*
|
1997-06-25 |
1998-12-30 |
Boehringer Mannheim Italia S.p.A. |
Bis-Indole derivatives having antimetastatic activity, a process for their preparation and pharmaceutical compositions containing them
|
|
US6410584B1
(en)
*
|
1998-01-14 |
2002-06-25 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells with indole derivatives
|
|
GB9818730D0
(en)
|
1998-08-27 |
1998-10-21 |
Univ Portsmouth |
Collections of compounds
|
|
DE69930328T2
(de)
|
1998-08-27 |
2006-12-14 |
Spirogen Ltd., Ryde |
Dimere Pyrrolobenzodiazepine
|
|
US6909006B1
(en)
*
|
1999-08-27 |
2005-06-21 |
Spirogen Limited |
Cyclopropylindole derivatives
|
|
EP2357009A1
(en)
|
2002-07-15 |
2011-08-17 |
Board of Regents, The University of Texas System |
Duramycin peptide binding to anionic phospholipids and aminophospholipids conjugates and their use in treating viral infections
|
|
GB0226593D0
(en)
|
2002-11-14 |
2002-12-24 |
Consultants Ltd |
Compounds
|
|
ZA200507752B
(en)
*
|
2003-03-28 |
2007-01-31 |
Threshold Pharmaceuticals Inc |
Compositions and methods for treating cancer
|
|
GB0321295D0
(en)
|
2003-09-11 |
2003-10-15 |
Spirogen Ltd |
Synthesis of protected pyrrolobenzodiazepines
|
|
CN102746336B
(zh)
|
2005-06-29 |
2015-08-19 |
施瑞修德制药公司 |
氨基磷酸酯烷化剂前体药物
|
|
EP1994000B1
(en)
*
|
2006-02-02 |
2017-08-23 |
Syntarga B.V. |
Water-soluble cc-1065 analogs and their conjugates
|
|
GB0619325D0
(en)
*
|
2006-09-30 |
2006-11-08 |
Univ Strathclyde |
New compounds
|
|
EP2114157B1
(en)
*
|
2006-12-26 |
2021-05-26 |
ImmunoGenesis, Inc. |
Phosphoramidate alkylator prodrug for the treatment of cancer
|
|
US9901567B2
(en)
|
2007-08-01 |
2018-02-27 |
Syntarga B.V. |
Substituted CC-1065 analogs and their conjugates
|
|
US20090118031A1
(en)
*
|
2007-11-01 |
2009-05-07 |
Qualizza Gregory K |
Shaft Structure with Configurable Bending Profile
|
|
ES2572356T3
(es)
|
2007-11-09 |
2016-05-31 |
Peregrine Pharmaceuticals Inc |
Composiciones de anticuerpos dirigidos contra VEGF y procedimientos
|
|
UY31506A1
(es)
*
|
2007-12-03 |
2009-08-03 |
|
Derivados de indolinona y procedimiento para su preparacion
|
|
AU2009320481C1
(en)
|
2008-11-03 |
2016-12-08 |
Syntarga B.V. |
Novel CC-1065 analogs and their conjugates
|
|
AU2011243294C1
(en)
|
2010-04-21 |
2015-12-03 |
Syntarga B.V. |
Novel conjugates of CC-1065 analogs and bifunctional linkers
|
|
US9056874B2
(en)
|
2012-05-04 |
2015-06-16 |
Novartis Ag |
Complement pathway modulators and uses thereof
|
|
EP2970269B1
(en)
|
2013-03-14 |
2017-04-19 |
Novartis AG |
2-(1h-indol-4-ylmethyl)-3h-imidazo[4,5-b]pyridine-6-carbonitrile derivatives as complement factor b inhibitors useful for the treatment of ophthalmic diseases
|
|
EP3089963A1
(en)
|
2013-10-30 |
2016-11-09 |
Novartis AG |
2-benzyl-benzimidazole complement factor b inhibitors and uses thereof
|
|
AU2015205574B2
(en)
|
2014-01-10 |
2019-08-15 |
Byondis B.V. |
Method for purifying Cys-linked antibody-drug conjugates
|
|
AU2022238571A1
(en)
|
2021-03-18 |
2023-09-14 |
Seagen Inc. |
Selective drug release from internalized conjugates of biologically active compounds
|